Fairvalue-Calculator Fairvalue-Calculator
EN DE

Shanghai Hile Bio-Technology Co (603718) Fair Value & Analysis

Healthcare · CN · Market cap 2.0B CNY

Price¥3.02
Fair Value¥1.24
Upside-58.9%
Quality93/100
Evidence: High Range ¥0.9200 – ¥1.82

Fair value as of: Jun 24, 2026

Analysis

Shanghai Hile Bio-Technology Co (603718) currently trades at ¥3.02, while our model-based Fair Value estimate is ¥1.24 — implying the stock looks roughly 58.9% overvalued today. We read business quality at 93/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Shanghai Hile Bio-Technology Co., Ltd. develops, manufactures, and sells in vitro diagnostic reagents and oral tissue repair and regeneration materials in China. It operates through two segments: In Vitro Diagnostic Reagents and Oral Tissue Repair and Regeneration Materials. The In Vitro Diagnostic Reagents segment offers biochemical diagnostic reagents, immuno-latex reagents, immune turbidimetry reagents, latex enhanced immune turbidimetry reagents, enzyme-linked immunosorbent products, and related diagnostic kits, including matrix metalloproteinase 3, IV collagen, adiponectin, creatine kinase isoenzyme, hepatic bile acid, cardiac troponin I, heparin binding protein, hemoglobin A1C, lipoprotein phospholipase A2, heart fatty acid binding protein, ferritin, sialoglycoside antigen, and procalcitonin kits. The Oral Tissue Repair and Regeneration Materials segment provides oral bone repair materials, implant systems, natural bone repair materials, oral restorative films, collagen-based …

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Shanghai Hile Bio-Technology Co (603718) undervalued?
As of Jun 24, 2026, our model estimates a fair value of ¥1.24 versus a price of ¥3.02 — about −59% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 603718?
Our 21-model fair value for Shanghai Hile Bio-Technology Co is ¥1.24 (as of Jun 24, 2026), built from audited fundamentals. The current price is ¥3.02.
What is the quality score of 603718?
Shanghai Hile Bio-Technology Co has a Quality Score of 93/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.